Today, the FDA approved the targeted therapy combination of vemurafenib (Zelboraf®) with cobimetinib (Cotellic) for people who have advanced or metastatic melanoma and who...

Washington, D.C. – On Saturday, November 7th, the Washington, D.C. melanoma community will come together to honor those who have been impacted by melanoma and raise f...

Statement from Tim Turnham, Executive Director, Melanoma Research Foundation   Washington, D.C.—Today the Food and Drug Administration (FDA) approved ipilimumab ...

For the last decade, Dr. Richard Carvajal has dedicated his career to the research and treatment of rare cancers like ocular melanoma (OM) and understands the need for more...

  Statement from Tim Turnham, Executive Director, Melanoma Research Foundation   The Melanoma Research Foundation (MRF) applauds the FDA’s approval of the c...

  Organization Remains Only Melanoma-Dedicated Nonprofit in the U.S. To Receive Ranking   WASHINGTON, D.C.— The Melanoma Research Foundation’s (MRF) s...

  Leading Nonprofits in Melanoma Commend Committee’s Ongoing Support and Dedication to Advancing Breakthrough Melanoma Treatments   WASHINGTON, D.C. —...

CURE TEAMS UP WITH MELANOMA RESEARCH FOUNDATION AND AIM AT MELANOMA TO COLLABORATE IN ADVOCACY SPOTLIGHT PARTNERSHIP PROGRAM   PLAINSBORO, N.J. (June 4, 2015) — ...

Representatives Maloney & Fitzpatrick request $50 million for rare cancer (including melanoma) research in FY16.

Meeting summary written by By Esther Damaser, Ph.D., ocular melanoma survivor and CURE OM Patient Steering Committee member.

WASHINGTON, D.C.— The Community United for Research and Education of Ocular Melanoma (CURE OM) commends Oliver Sacks for bravely sharing his experiences with ocular m...